Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

Timothy M. Schmidt1, Benjamin G. Barwick1, Nisha Joseph1, Leonard T. Heffner1, Craig C. Hofmeister1, Leon Bernal1, Madhav V. Dhodapkar1, Vikas A. Gupta1, David L. Jaye2, Jiayi Wu3, Subir Goyal3, Zhengjia Chen3, Lawrence H. Boise1, Sagar Lonial1, Ajay K. Nooka1 and Jonathan L. Kaufman1

Abstract
Gain of chromosome 1q (+1q) is commonly identified in multiple myeloma and has been associated with inferior outcomes. However, the prognostic implication of +1q has not been evaluated in the setting of standard triplet regimens. We retrospectively analyzed 201 consecutive patients with newly diagnosed myeloma who received induction with lenalidomide, bortezomib, and dexamethasone (RVD) and were tested for +1q at diagnosis by fluorescent in-situ hybridization. Patients with +1q (n = 94), compared to those without +1q (n = 107), had shorter median progression-free survival (PFS) (41.9 months vs 65.1 months, p = 0.002, HR = 1.90) and overall survival (median not reached (NR) for either arm, p = 0.003, HR 2.69). In subgroup analyses, patients with co-occurring +1q and t(4;14), t(14;16) or del(17p) or with 4 or more copies of 1q had significantly worse PFS (25.1 months and 34.6 months, p < 0.001 and p = 0.0063, respectively), whereas patients with three copies and no other high-risk cytogenetic abnormalities had no significant difference in PFS. These data suggest that when treated with RVD induction, patients with +1q should be considered at very high risk for early progression in multiple myeloma when ≥4 copies are detected or in the context of other high-risk cytogenetic abnormalities.

Introduction
Multiple myeloma (MM), a malignant neoplasm of plasma cells, is the second most common hematological malignancy in the United States and is characterized by marked clinical heterogeneity and variable outcomes. One of the most important factors determining prognosis for patients with MM is the presence or absence of recurrent chromosomal abnormalities as detected by karyotype and/or fluorescence in-situ hybridization (FISH). It is now well-established that the presence of t(4;14), t(14;16), and/or del(17p) by FISH is associated with early progression and shorter overall survival, and these have been incorporated into the Revised International Scoring System (R-ISS) that predicts survival times for patients with newly diagnosed MM.

Gain of chromosome 1q (+1q) is one of the most common cytogenetic abnormalities in patients with MM, occurring in ~35–40% of patients. Many investigators have examined the prognostic implication of +1q, but there remains debate regarding its significance. While some studies have found that +1q is an independent predictor of poor outcomes, other studies have not shown this correlation. Furthermore, these studies have all generally been performed prior to the widespread...
implementation of novel induction regimens containing the combination of a proteasome inhibitor, immunomodulatory agent, and steroid. Although it has been suggested that bortezomib-based regimens can overcome the negative prognostic impact of +1q, its negative impact on prognosis was maintained in other cohorts. Studies that have evaluated the impact of +1q on outcomes of patients treated with novel induction regimens have suggested that +1q remains a poor prognostic factor, but conclusions are limited by small sample size and patient selection bias.

It has generally been understood that gain of 1q frequently occurs with disease progression, often by “jumping” translocations and that the copy number can increase over time, with higher rates of +1q detection after progression from the precursor conditions, monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. It has been suggested that any negative impact on survival with +1q may be more pronounced with amplification of 1q (amp(1q)), defined 4 or more copies of chromosome 1q or with co-occurrence of deletion of chromosome 1p (del(1p))13,16. However, the molecular mechanism by which +1q impacts myeloma biology, development, and progression remains poorly understood. Gene expression profiling studies have shown extensive dysregulation of multiple genes on chromosome 1, with a resultant negative impact on prognosis. Overexpression of CKS1B was originally identified as a potential driver gene on 1q, but several other genes of interest including ADAR1 and MCL1 have been suggested more recently.

Induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) is a highly active regimen in MM with substantial progression-free and overall survival benefits for patients over therapy with lenalidomide and dexamethasone alone, and is effective both for patients who proceed to autologous stem cell transplantation (ASCT) or those who are not eligible for ASCT. Although this highly active regimen was only recently implemented as standard of care across North America and parts of Europe, RVD has been utilized at our institution for over 12 years. By analyzing our large cohort of patients who were treated uniformly with highly active novel induction therapy, we aimed to determine whether patients with +1q had any distinct clinical features or differences in outcomes compared to patients without +1q.

Methods

Patients and demographics
We performed a retrospective analysis of all patients with MM who were seen for an initial visit at Winship Cancer Institute of Emory University between 1 November 2010 and 31 December 2014 and were treated with RVD induction therapy. Patients were identified through an Institutional Review Board-approved myeloma outcomes database that includes all myeloma patients seen at Winship Cancer Institute, with pathological data supplied by the clinical pathology database at Emory University Hospital. Patients in the database were screened by their induction regimen, and patients who were documented as having received induction therapy with RVD were selected for consideration in our analysis. Patients’ electronic health records were reviewed individually in order to confirm their induction treatment and adequacy of diagnostic testing at diagnosis. In order to eliminate the possibility of bias due to clonal cytogenetic evolution seen at relapse, patients were excluded from the analysis if the biopsy report from diagnosis was not available, if it did not have sufficient material for cytogenetic testing, if it was not tested for +1q, or if extra copies of chromosome 1q were only detected by conventional karyotype. Among patients whose diagnostic bone marrows were not enriched for CD138 cells, we included patients if +1q was detected, but excluded those for which +1q was not detected because of uncertainty regarding the presence or absence of 1q gain. A cut-off date for follow up was set at 31 October 2018.

Baseline demographic information (age, sex, race, ethnicity), and laboratory values (hemoglobin, creatinine, calcium, albumin, lactate dehydrogenase (LDH), beta-2-microglobulin (β2M), isotype, M-spike, and serum free light chains) were recorded from the time of diagnosis. Patients were classified by their International Staging System (ISS) stage and Revised International Staging System (R-ISS) at diagnosis. The presence of t(11;14), t(4;14), t(14;16), del(17p), del(13), +1q, and del(1p) were determined by FISH at the time of diagnosis. Patients were also categorized as to whether they had a complex karyotype (defined as three or more abnormalities on conventional cytogenetics). Data regarding date of diagnosis, treatment initiation, ASCT, maintenance therapy, best response to induction therapy and transplantation, and dates of first progression and death were collected. Patient charts were reviewed individually, and data was verified for each patient. External records were reviewed, if available, for patients who were initially diagnosed and/or treated at another medical center.

Outcomes
The primary outcomes of interest for this study were best response to RVD induction therapy, median PFS, and median overall survival (OS) for patients with +1q compared to patients without +1q. For patients who were treated with autologous stem cell transplantation, responses to transplant and post-transplant PFS and OS were also evaluated. For patients with +1q, additional information was collected and analyzed for copy number
(gain(1q), defined as three copies of chromosome 1q, versus amp(1q), defined as four or more copies of 1q) and allele frequency (defined as greater or less than 20% of cells by FISH).

Statistical analysis
Statistical analysis was conducted using SAS Version 9.4. In the descriptive analysis, $p$-values were calculated using chi-square or Fisher’s exact test. Cox proportional hazard model was employed for the multivariate analysis, including all variables that were significant in the univariate analysis and using backward elimination to exclude variables with $p \geq 0.1$. To calculate PFS and OS, the Kaplan–Meier method was utilized, and significance between groups was calculated using the log-rank test. A $p$-value of <0.05 was considered as statistically significant for all analyses.

Analysis of the CoMMpass study
Analysis of the Clinical Outcomes in Multiple Myeloma to Personal Assessment (CoMMpass) trial (NCT01454297) was similar to that previously described. Briefly, outcome data made use of the interim analysis 13 and analysis was restricted to 795 baseline specimens where outcome and long-insert whole genome sequencing data were available in dbGaP (phs000748.v6.p4). Copy number alterations (CNA) at 1q21 were estimated relative to non-myeloma peripheral blood samples using tCoNut (https://github.com/tgen/tCoNuT) as provided in interim analysis 13. Survival analysis made use of the “survival” (v2.43-3) package in R/Bioconductor (v3.6.0). Differences in PFS and OS were determined using a cox proportional hazards regression fit to discrete groups determined by log2 CNA and $p$-values were calculated using a Wald’s test. Relevant clinical and demographic data (age, ISS stage, $\beta2$ M levels, M protein levels, gender, race, and front-line therapy) where analyzed between patients with a 1q gain or amplification as compared to those without. Factors that were significantly different in 1q gain or amplified patients were considered in a multivariate analysis with 1q copy number to determine if 1q was an independent prognostic factor.

Results
Our search identified 553 consecutive patients who were seen at Winship Cancer Institute of Emory University and were treated with RVD induction for MM. After excluding patients who were not tested for +1q at diagnosis or for whom presence/absence of +1q at diagnosis could not be confirmed, a total of 201 patients were identified as suitable for the final analysis. Methodology by which patients were excluded is detailed in Fig. 1. Of these 201 patients for whom complete diagnostic information was available at diagnosis, 94 (46.7%) had at least one extra copy of chromosome 1q by FISH. Median duration of follow up was 48 months among evaluable patients.

Patient characteristics are summarized in Table 1. Median age at diagnosis was 64 and was not different between groups. Patients with +1q were more likely to present with anemia and/or thrombocytopenia, had higher beta-2-microglobulin, and had a higher ISS and R-ISS stage. Additionally, patients with +1q at diagnosis were more likely to have co-occurrence of t(4;14), t(14;16), del(13q), del(1p), and complex karyotype at

![Fig. 1 Method of patient selection in final analysis. Flow diagram depicting how patients from the Emory University database were selected for evaluation in the final analysis. Patient records were reviewed individually, induction with RVD was verified, and all pathology reports were reviewed to confirm testing for +1q. Patients were excluded if +1q was tested only at relapse. Patients were also excluded if +1q was not identified on samples not enriched for CD138+ cells or if +1q was detected only by conventional karyotype and not by FISH.](https://example.com/image.png)
Table 1  Patient characteristics.

| Characteristic          | No  | +1q        | +1q        | Total | P-value |
|-------------------------|-----|------------|------------|-------|---------|
| Age (years)             |     |            |            |       |         |
| Median                  | 63  | 64         | 64         |       |         |
| ≥ 65                    | 44  | 41.1%      | 43         | 45.7% | 87      | 43.3%  | 0.509 |
| < 65                    | 63  | 58.9%      | 51         | 54.3% | 114     | 56.7%  |       |
| Sex                     |     |            |            |       |         |
| Male                    | 64  | 59.8%      | 50         | 53.2% | 114     | 56.7%  | 0.344 |
| Female                  | 43  | 40.2%      | 44         | 46.8% | 87      | 43.3%  |       |
| Race                    |     |            |            |       |         |
| African-American        | 34  | 31.8%      | 21         | 22.3% | 55      | 27.4%  | 0.186 |
| Caucasian               | 63  | 58.9%      | 67         | 71.3% | 130     | 64.7%  |       |
| Unknown/Other           | 10  | 9.3%       | 6          | 6.4%  | 16      | 8.0%   |       |
| Isotype                 |     |            |            |       |         |
| IgG                     | 66  | 61.7%      | 45         | 47.9% | 111     | 55.2%  | 0.158 |
| IgA                     | 19  | 17.8%      | 27         | 28.7% | 46      | 22.9%  |       |
| IgD                     | 1   | 0.9%       | 0          | 0.0%  | 1       | 0.5%   |       |
| FLC                     | 20  | 18.7%      | 20         | 21.3% | 40      | 19.9%  |       |
| Nonsecretory            | 1   | 0.9%       | 1          | 1.1%  | 2       | 1.0%   |       |
| Oligosecretory          | 0   | 0.0%       | 1          | 1.1%  | 1       | 0.5%   |       |
| Hemoglobin (g/dL)       |     |            |            |       |         |
| Median                  | 11  | 10         | 10.5       |       |         |
| <10                     | 26  | 26.8%      | 39         | 45.9% | 65      | 35.7%  | 0.007 |
| ≥10                     | 71  | 73.2%      | 46         | 54.1% | 117     | 64.3%  |       |
| Platelets (x10^3/µL)    |     |            |            |       |         |
| Median                  | 218 | 186.5      | 207        |       |         |
| <150                    | 11  | 12.6%      | 23         | 30.3% | 34      | 20.9%  | 0.006 |
| ≥150                    | 76  | 87.4%      | 53         | 69.7% | 129     | 79.1%  |       |
| Creatinine (mg/dL)      |     |            |            |       |         |
| Median                  | 1.01| 1.03       | 1.02       |       |         |
| >2.0                    | 8   | 8.6%       | 11         | 13.6% | 19      | 10.9%  | 0.294 |
| ≤2.0                    | 85  | 91.4%      | 70         | 86.4% | 155     | 89.1%  |       |
| Calcium (mg/dL)         |     |            |            |       |         |
| Median                  | 9.2 | 9.4        | 9.2        |       |         |
| >10.5                   | 3   | 3.6%       | 13         | 16.3% | 16      | 9.8%   | 0.006 |
| ≤10.5                   | 81  | 96.4%      | 67         | 83.8% | 148     | 90.2%  |       |
| Albumin (g/dL)          |     |            |            |       |         |
| Median                  | 3.7 | 3.6        | 3.6        |       |         |
| >3.5                    | 36  | 37.9%      | 35         | 44.9% | 71      | 41.0%  | 0.353 |
| ≤3.5                    | 59  | 62.1%      | 43         | 55.1% | 102     | 59.0%  |       |
| LDH (units/L)           |     |            |            |       |         |
| Median                  | 133 | 154.5      | 150        |       |         |
| >ULN                    | 3   | 5.0%       | 5          | 7.9%  | 8       | 6.5%   | 0.718 |
| ≤ULN                    | 57  | 95.0%      | 58         | 92.1% | 115     | 93.5%  |       |
| β2M (mg/L)              |     |            |            |       |         |
| Median                  | 2.83| 3.8        | 2.95       |       |         |
| >5.5                    | 11  | 11.8%      | 20         | 26.7% | 31      | 18.5%  | 0.014 |
| ≤5.5                    | 82  | 88.2%      | 55         | 73.3% | 137     | 81.5%  |       |
| M-spike (g/dL)          |     |            |            |       |         |
| Median                  | 1.99| 2.7        | 2.24       |       |         |
| >3.0                    | 34  | 37.8%      | 37         | 45.1% | 71      | 41.3%  | 0.329 |
| ≤3.0                    | 56  | 62.2%      | 45         | 54.9% | 101     | 58.7%  |       |
| FLC Ratio >100 or <0.001| 42  | 48.8%      | 46         | 60.5% | 88      | 54.3%  | 0.136 |
diagnosis. There was no significant difference between groups in the frequency of upfront ASCT or whether maintenance therapy was prescribed.

Response rates and survival outcomes

Best response to RVD induction is shown in Fig. 2. Overall response rate was similar for patients with +1q and patients without +1q, (98.9% vs 98.1%). However, patients with +1q had significantly deeper responses; in particular, patients with +1q were more likely to achieve a VGPR or better compared to patients without +1q (75.0% vs 59.8%, $p = 0.02$).

Kaplan–Meier curves for PFS and OS are shown in Fig. 3. Median PFS for patients with +1q patients was 41.9 months (95% CI 32.6–63.3 mo) compared with 65.1 months (95% CI 53.4 mo–NR) among patients who did not have +1q ($p = 0.002$, HR 1.91). Patients with +1q had a 5-year PFS rate of 41.3% (95% CI 29.9–52.4%) compared to 54.6% (42.4–65.3%) for patients without +1q. Median OS was NR in either group, but Kaplan–Meier curves had clear early separation and patients with +1q had significantly inferior OS rates compared to those without +1q ($p = 0.0024$, HR 2.69). Five-year OS rate for patients with +1q was 66.9% (95% CI 54.9–76.4%), which is significantly lower than the 5-year OS rate of 88.5% (95% CI 79.7–93.7%) among patients without +1q.

On univariate analysis, calcium > 10.5 mg/dL, lack of maintenance therapy, t(4;14), t(14;16), del(17p), del(13q), complex karyotype, and +1q were identified as factors.
significantly associated with worse PFS. Comprehensive results from univariate analysis are shown in Table 2. On multivariate analysis, +1q retained its negative impact on PFS ($p = 0.018$, HR 1.89, 95% CI 1.11–3.20). Other factors that were significant in multivariate analysis included maintenance therapy, which was associated with significantly improved PFS, as well as calcium >10.5, t(4;14), t(14;16), and del(17p) which were all significantly associated with worse PFS (Table 3).

Outcomes of patients undergoing upfront ASCT
Seventy-six of 94 (80.9%) patients with +1q and 89 of 107 (83.1%) patients without +1q underwent ASCT. Among the 76 patients with +1q who did receive a transplant, 73 (96.1%) of them achieved a VGPR or better compared to 75 of 89 (84.3%) patients achieving a VGPR after transplant among patients who did not have +1q ($p = 0.01$). As seen in Fig. 2, the difference between groups was primarily driven by the high rate of CR (82.9%) among patients with +1q compared to those without +1q (66.3%). Despite the improved response rates, median PFS was significantly shorter among transplanted patients with +1q (42.1 months; 95% CI 32.8–78.9 mo) compared to transplanted patients without +1q (71.5 months; 95% CI 52.5mo–NR) ($p = 0.0136$). Median OS was NR for either arm, but five-year OS after transplant was 66.8% (95% CI 53.4–77.1%) for patients with +1q compared to 88.4% (95% CI 78.9–93.8%) for patients without +1q ($p = 0.006$).

Impact of co-occurring cytogenetic abnormalities
Among the 201 patients in this series, 40 (19.9%) were identified as high-risk by consensus criteria (defined by the presence of t(4;14), t(14;16), and/or del(17p) by FISH). Among high-risk patients, +1q was also identified in 28 (70% of high-risk patients). Median PFS of high-risk patients also harboring +1q was 25.1 months (95% CI 12.0–32.6 mo), which was significantly worse than high-risk patients who did not have +1q ($p = 0.02$). Patients with +1q who did not have other high-risk cytogenetic abnormalities ($n = 66$) had a median PFS of 61.3 months (95% CI 37.9–78.9 mo), which is significantly better than those with high risk and +1q ($p < 0.001$). The median PFS of the 95 patients without high-risk cytogenetics or +1q was 65.1 months (95% CI 52.5 mo–NR), which is not significantly different compared to the PFS of patients with +1q but no other high-risk cytogenetic abnormalities ($p = 0.1817$). These findings are demonstrated in Fig. 4a.

Impact of copy number and detection threshold
Among patients with +1q, we sought to determine whether 1q copy number, percentage of cells with +1q by FISH, and/or co-occurrence of del(1p) impacted outcomes among patients with +1q. Among the 94 patients with +1q, 78 had copy number quantified in the FISH report. 52 (66.7%) had only one additional copy identified at the time of diagnosis (three copies) and 26 (33.3%) had two or more extra copies of chromosome 1q (four or more copies/amp(1q)). There were no significant differences in baseline characteristics or cytogenetics between patients with amp(1q) compared to those with gain(1q) (Supplementary Table 1). Patients with three copies of 1q had a median PFS of 55.9 months (32.6–78.9 mo) and those with amp(1q) had a median PFS of 34.6 months (15.6–61.1 months). When compared to the median PFS

---

**Fig. 2 Best response to RVD and ASCT.** Percentage of patients achieving at least a complete response ($\geq$CR), very good partial response ($\geq$VGPR), and partial response ($\geq$PR) to RVD induction and ASCT is demonstrated. Patients were grouped by presence or absence of +1q and best response after completion of induction or transplant.
of 65.1 months for the cohort without +1q, these outcomes were significantly different ($p = 0.0063$), as demonstrated in Fig. 4b. Impact of 1q copy number by cytogenetic risk is shown in Fig. 4c, d. Among patients with standard risk cytogenetics, those with 2, 3, or ≥4 copies had a median PFS of 65.0 months (95% CI 52.4 mo–NR), 74.5 months (55.9–78.8 mo), and 34.7 months (15.6–61.1 mo), respectively. Among patients with high-risk cytogenetics, median PFS for patients with 2, 3, or ≥4 copies was NR (16.3mo–NR), 23 months (11.0–27.1 mo), and 26.8 months (10.3 mo–NR).

There was no significant difference in PFS among patients with 20% or more cells positive for +1q compared to those with <20% by FISH ($p = 0.1837$, data not shown). Of 88 patients with +1q who were also tested for del(1p), 15 patients also had del(1p) by FISH at the time of diagnosis (17.0%), but there was no difference in PFS between these patients and those with +1q alone ($p = 0.9753$, data not shown).

Impact of Chromosome 1q copy number alteration in the CoMMpass Trial

We sought to validate our findings using an independent dataset and thus made use of the Multiple Myeloma Research Foundation’s CoMMpass trial, which is a large, multinational, prospective cohort study that enrolled 1150 patients and analyzed the majority of samples using multiple genomic technologies. We restricted our analysis
### Table 2  Univariate analysis.

| Characteristic | N   | Hazard ratio (95% CI) | HR P-value | Log-rank P-value |
|----------------|-----|-----------------------|------------|------------------|
| **Age**        |     |                       |            |                  |
| ≥65            | 114 | 0.79 (0.52–1.20)      | 0.264      | 0.262            |
| <65            | 87  | Ref                   |            |                  |
| **Sex**        |     |                       |            |                  |
| Male           | 114 | 1.15 (0.75–1.76)      | 0.514      | 0.513            |
| Female         | 87  | Ref                   |            |                  |
| **Race**       |     |                       |            |                  |
| African-American | 55 | 0.89 (0.54–1.46)      | 0.644      | 0.743            |
| Caucasian      | 130 | Ref                   |            |                  |
| Other/Unknown  | 16  | 0.73 (0.29–1.82)      | 0.504      |                  |
| **Isotype**    |     |                       |            |                  |
| IgG            | 111 | Ref                   |            | 0.171            |
| IgA            | 46  | 1.12 (0.68–1.87)      | 0.654      |                  |
| FLC            | 40  | 0.96 (0.55–1.68)      | 0.891      |                  |
| Others         | 4   | 3.44 (1.06–11.14)     | 0.04       |                  |
| **Hemoglobin** |     |                       |            |                  |
| <10            | 65  | 1.27 (0.80–2.00)      | 0.311      | 0.309            |
| ≥10            | 117 | Ref                   |            |                  |
| **Platelets**  |     |                       |            |                  |
| <150           | 34  | 1.32 (0.74–2.36)      | 0.34       | 0.338            |
| ≥150           | 129 | Ref                   |            |                  |
| **Creatinine** |     |                       |            |                  |
| >2.0           | 19  | 1.70 (0.87–3.31)      | 0.122      | 0.117            |
| ≤2.0           | 155 | Ref                   |            |                  |
| **Calcium**    |     |                       |            |                  |
| >10.5          | 16  | 3.29 (1.68–6.47)      | <0.001     | <0.001           |
| ≤10.5          | 148 | Ref                   |            |                  |
| **Albumin**    |     |                       |            |                  |
| <3.5           | 71  | 0.75 (0.46–1.22)      | 0.245      | 0.242            |
| ≥3.5           | 102 | Ref                   |            |                  |
| **LDH**        |     |                       |            |                  |
| <ULN           | 115 | 1.06 (0.26–4.38)      | 0.934      | 0.934            |
| ≥ULN           | 8   | Ref                   |            |                  |
| **β2M**        |     |                       |            |                  |
| >5.5           | 31  | 1.15 (0.66–2.00)      | 0.63       | 0.629            |
| ≤5.5           | 137 | Ref                   |            |                  |
| **M-spike**    |     |                       |            |                  |
| >3.0           | 71  | 0.92 (0.58–1.47)      | 0.741      | 0.741            |
| ≤3.0           | 101 | Ref                   |            |                  |
| **FLC Ratio**  |     |                       |            |                  |
| >100 or <0.001 | 88  | 1.48 (0.90–2.42)      | 0.122      | 0.119            |
| 0.001 < k/l < 100 | 74 | Ref                   |            |                  |
| **ISS**        |     |                       |            |                  |
| 1              | 66  | Ref                   |            | 0.966            |
| 2              | 68  | 1.00 (0.60–1.67)      | 0.995      |                  |
| 3              | 33  | 1.08 (0.59–1.98)      | 0.813      |                  |
| **R-ISS**      |     |                       |            |                  |
| 1              | 40  | Ref                   |            | 0.294            |
| 2              | 75  | 1.27 (0.70–2.30)      | 0.44       |                  |
| 3              | 12  | 2.10 (0.82–5.39)      | 0.124      |                  |
| **Upfront transplant** |     |                       |            |                  |
| Yes            | 157 | 0.71 (0.41–1.24)      | 0.226      | 0.223            |
| No             | 44  | Ref                   |            |                  |
| **Maintenance** |     |                       |            |                  |
| Yes            | 155 | 0.49 (0.29–0.83)      | 0.008      | 0.007            |
| No             | 40  | Ref                   |            |                  |
to 870 newly diagnosed patients with outcome data and 1q21 copy number alterations (CNA) derived from whole genome long-insert sequencing. Comparison of demographics, baseline clinical characteristics, induction regimens, of CoMMpass patients with +1q compared to those without +1q is demonstrated in Supplementary Fig. 1A–G. Similar to patients treated at Emory, CoMMpass patients with +1q tended to have a higher ISS stage, age, and beta-2-microglobulin levels.

Analysis of 1q21 copy number represented as a log2 ratio relative to normal peripheral blood from the same patient, clearly delineated patients with two copies (log ratio ~ 0) from those with three (log ratio ~ 0.5) or four copies (log ratio ~ 1) (Fig. 5a). Of the 870 evaluable patients in the CoMMpass database, 575 (66.1%) did not have +1q and 295 (33.9%) had +1q. Among patients with +1q, 242 (82.0%) had one additional copy and 53 (18.0%) had two or more additional copies of 1q. Survival analysis of these patients indicated that three copies of 1q had significantly inferior PFS and OS compared to those with two copies (p = 0.018 and p = 0.004, respectively). Patients with four or more copies of 1q had significantly worse PFS compared to those with three copies (p = 0.019) and had a trend towards inferior OS (p = 0.062) (Fig. 5b). Importantly, +1q remained significant on multivariate analysis when controlling for differences in clinical data among CoMMpass patients (Supplementary Fig. 1H). These data support our observations that reduced PFS and OS occur with increasing 1q amplification.

### Table 2 continued

| Characteristic | N   | Hazard ratio (95% CI) | HR P-value | Log-rank P-value |
|----------------|-----|-----------------------|------------|-----------------|
| t(11;14)       |     |                       |            |                 |
| Yes            | 35  | 0.86 (0.49–1.54)      | 0.619      | 0.618           |
| No             | 157 | Ref                   |            |                 |
| t(4;14)        |     |                       |            |                 |
| Yes            | 9   | 2.45 (1.06–5.63)      | 0.035      | 0.029           |
| No             | 184 | Ref                   |            |                 |
| t(14;16)       |     |                       |            |                 |
| Yes            | 9   | 2.77 (1.12–6.88)      | 0.028      | 0.022           |
| No             | 182 | Ref                   |            |                 |
| del(17p)       |     |                       |            |                 |
| Yes            | 24  | 2.53 (1.40–4.59)      | 0.002      | 0.001           |
| No             | 173 | Ref                   |            |                 |
| del(13q)       |     |                       |            |                 |
| Yes            | 84  | 1.71 (1.13–2.60)      | 0.011      | 0.01            |
| No             | 112 | Ref                   |            |                 |
| Hyperdiploidy  |     |                       |            |                 |
| Yes            | 121 | 0.73 (0.47–1.15)      | 0.174      | 0.172           |
| No             | 69  | Ref                   |            |                 |
| del(1p)        |     |                       |            |                 |
| Yes            | 21  | 1.27 (0.66–2.46)      | 0.473      | 0.472           |
| No             | 172 | Ref                   |            |                 |
| Complex Karyotype |   |                       |            |                 |
| Yes            | 44  | 2.05 (1.30–3.22)      | 0.002      | 0.002           |
| No             | 155 | Ref                   |            |                 |
| Gain(1q)       |     |                       |            |                 |
| Yes            | 94  | 1.91 (1.26–2.91)      | 0.003      | 0.002           |
| No             | 107 | Ref                   |            |                 |

### Table 3 Multivariate analysis.

|                     | N  | Hazard ratio (95% CI) | HR P-value |
|---------------------|----|-----------------------|------------|
| Calcium             |    |                       |            |
| >10.5               | 16 | 2.34 (1.04–5.28)      | 0.04       |
| ≤10.5               | 148| Ref                   |            |
| Maintenance         |    |                       |            |
| Yes                 | 155| 0.45 (0.22–0.92)      | 0.029      |
| No                  | 40 | Ref                   |            |
| t(4;14)             |    |                       |            |
| Yes                 | 9  | 4.18 (1.46–11.96)     | 0.008      |
| No                  | 184| Ref                   |            |
| t(14;16)            |    |                       |            |
| Yes                 | 9  | 2.80 (1.07–7.34)      | 0.036      |
| No                  | 182| Ref                   |            |
| del(17p)            |    |                       |            |
| Yes                 | 24 | 2.52 (1.25–5.09)      | 0.01       |
| No                  | 173| Ref                   |            |
| Gain(1q)            |    |                       |            |
| Yes                 | 94 | 1.92 (1.14–3.25)      | 0.015      |
| No                  | 107| Ref                   |            |
Discussion

In this study, we sought to characterize the clinical characteristics and outcomes of patients with multiple myeloma harboring +1q at diagnosis in the era of novel induction therapy. Although large, prospective studies have been performed in the past with attention to the impact of +1q on outcomes\(^2\),\(^6\),\(^25\), the relevance of the prognostic impact of +1q in those studies uncertain as these older regimens including thalidomide and/or chemotherapy are not widely used in current myeloma treatment regimens. RVD has become the new standard of care in the United States based on its remarkable efficacy in both transplant-eligible and ineligible patients\(^22\),\(^23\). Our analysis is the largest to date that evaluates the prognostic impact of +1q in patients treated with RVD.

In our analysis, we found that among patients who were tested for the presence of +1q by FISH at diagnosis, +1q was seen 46.7% of newly diagnosed cases. Compared to patients without +1q, those with +1q at diagnosis were more likely to present with anemia, thrombocytopenia, high disease burden as signified by beta-2-microglobulin, and higher ISS stage. Additionally, +1q was highly associated with the co-occurrence of high-risk cytogenetic abnormalities including t(4;14), t(14;16) as tested by FISH, and complex karyotype by conventional karyotype, however there was no significant difference in co-occurrence of del(17p).

We found in our analysis that patients with +1q had a significantly higher chance of achieving a VGPR or CR with induction therapy. Despite these deeper responses, the presence of +1q was associated with significantly shorter PFS and OS compared to patients without +1q. This impact on prognosis remained significant even among patients who underwent consolidation with ASCT in first remission, despite 96% of patients with +1q achieving a VGPR or better after ASCT. We noted a
significant decrease in PFS with increasing copy number of +1q, as shown in Fig. 4b, with remarkably similar findings among patients in CoMMpass (Fig. 5b). Whether +1q is itself a driver of these inferior outcomes is unclear, as there was no significant difference in PFS between standard risk patients with or without gain of one copy of 1q (Fig. 4c). However, all patients with amp(1q) and high-risk patients with +1q, regardless of copy number, had substantial reduction in PFS (Fig. 4c, d). As seen in Fig. 4a, the data suggest that standard risk patients with +1q and high-risk patients without +1q may have an intermediate risk of progression when treated with RVD induction, but our dataset was underpowered to make this conclusion. To test this hypothesis, we performed the same analysis within the CoMMpass database and found similar findings, as shown in Supplementary Fig. 2. These results suggest that the combination of +1q and another high-risk CA or amp(1q) effectively result in a “ultra-high risk” subgroup that has dismal outcomes despite excellent response rates to RVD and high rates of ASCT.

Many other attempts have been made to risk stratify patients who are at high risk of early disease progression in order to identify patients who should be considered for novel treatment approaches. Recently, the concept of “double hit” myeloma has been proposed. In a large, international, cooperative study, whole-exome sequencing (WES) was performed in an attempt to identify genetic predictors of early disease relapse. In this study, the authors identified two populations at very high risk of early progression or death—the presence of bi-allelic inactivation of TP53 (by loss and/or mutation) and patients with 4 or more copies of CKS1B with ISS stage 3 disease. Notably, this study did not stratify patients by induction regimen. When evaluating only patients who were treated with RVD induction, our study complements the existing data that amp(1q) identifies a very high-risk patient population, and suggests that co-occurrence of +1q and t(4;14), t(14;16), or del(17p) may be another category of “double hit” patients who are at high risk for early progression despite aggressive treatment.

Our approach to the management of high-risk patients generally includes a risk-adapted maintenance strategy. We previously reported PFS and OS rates markedly superior to traditional benchmarks in high-risk patients with use of RVD maintenance for patients with t(4;14), t(14;16), del(17p) and/or complex karyotype. This approach highlights the fact that high-risk patients can achieve durable remissions if an aggressive approach is employed and that the depth of response is maintained for as long as possible. In this subset of patients, progressive disease leads to a vicious cycle of early progression on second-line therapies and beyond, with very few patients achieving durable second remissions. The current analysis demonstrates that +1q, when present with a high-risk cytogenetic abnormality, is associated with dismal outcomes, with a median PFS of only 25.1 months, compared to median PFS in excess of 60 months for all subgroups of patients without both factors. Of the 28 patients with +1q and additional high-risk CA, 20 (71%) were treated with maintenance therapy and 14 of these patients received some sort of risk-adapted maintenance therapy. While this subset is too small to draw any significant conclusions
regarding the benefit of risk-adapted maintenance, particularly within the retrospective nature of this analysis, the data suggest that patients with +1q and co-occurrence of other high-risk cytogenetic abnormalities may progress early despite risk-adapted maintenance, and this may be a unique subset of patients with multiple myeloma that should be considered for novel treatment approaches early in their disease course.

In the IFM2009 trial, a pre-planned analysis of outcomes according to minimal residual disease (MRD) was performed for patients who were treated with RVD induction and then randomized to ASCT or no transplant. In this analysis, it was clearly demonstrated that MRD negativity (at a depth of 10^-5) by next generation sequencing was a more powerful prognostic marker than cytogenetic risk, as patients with high-risk cytogenetics with MRD negativity had markedly better PFS than standard-risk patients who were MRD positive. Although information about MRD status was not available for the patients in our data set, the very high CR rate after transplant among patients with +1q raises the question of whether MRD is as powerful of a prognostic factor in these patients. Alternatively, it is possible that although RVD and ASCT are very effective at inducing a CR for +1q patients, MRD negativity could be more difficult to achieve in these patients. Notably, +1q data is not available from the IFM manuscripts, and this remains an unanswered question that should be evaluated in future analyses.

The primary strengths of this study include our large number of consecutive patients treated uniformly with RVD induction and a long duration of follow up, with restriction of patients to only those with high-quality diagnostic information. Importantly, our dataset is made up of a diverse patient population, which includes 31.8% African-American patients. This contrasts to other large datasets that have generally under-represented patients of African descent and makes our analysis more widely applicable. Our analysis is limited by the single-center, retrospective nature of the data collection, and the outcomes seen in this patient population may be biased by the fact that most patients are healthy enough to be considered for transplantation as the reason for referral to our center. Because we are largely a referral center, much of the data regarding labs and pathology at diagnosis is dependent on documentation by referring providers, resulting in missing data from the time of diagnosis. In particular, data for LDH and beta-2-microglobulin among patients referred from other medical centers were often missing and this may explain the lack of prognostic value of the ISS and R-ISS in our univariate analysis. However, the fact that we were able to show similar results for PFS among patients with +1q within CoMMpass, a large, prospective, multinational study, helps to validate our findings and broaden the applicability of our study. Of note, CoMMpass results must be interpreted with caution due to the heterogeneity of induction regimens used among these patients. Importantly, our analysis did not find confounding treatment regimens between +1q and other patients in CoMMpass (Supplementary Fig. 1).

In conclusion, patients with multiple myeloma who have +1q by FISH are more likely than those without +1q to present with anemia, thrombocytopenia, hypercalcaemia, higher ISS stage, and co-occurrence of high-risk cytogenetic abnormalities. Patients with +1q myeloma have significantly inferior PFS and OS compared to patients who do not have +1q despite having deeper responses to RVD induction therapy and ASCT. Although PFS is negatively impacted by the addition of one copy of 1q, having two or more additional copies of 1q at diagnosis is associated with significantly inferior PFS and OS compared to patients with only 3 copies of 1q. There is no significant impact on PFS or OS among standard-risk patients with gain(1q), but patients with +1q and any high-risk cytogenetic abnormality and patients with amp(1q), regardless of other cytogenetics, have extremely short PFS. Patients with amp(1q) and/or co-occurrence of +1q and high-risk cytogenetic abnormalities should be considered at very high risk for early progression or death and should be considered for more aggressive management and/or clinical trials early in their disease course.

Acknowledgements
This work was supported, in part, by the Winship Cancer Institute of Emory University and NIH/NCI award number P30CA138292 as well as by the Multiple Myeloma Research Foundation Answer Fund (LB). C.H. is supported by NIH/NCI award 5R01CA201382-03. B.B. is supported by Post-doctoral Fellowship PF-17-109-1-TBG from the American Cancer Society.

Author details
1Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA. 2Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA. 3Department of Biostatistics & Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.

Authors’ contributions
T.M.S. and J.J.K. designed the analysis. T.M.S. wrote the paper, reviewed individual patient records, verified accuracy of existing data, and supplemented existing data. N.J. had previously compiled data used in this analysis and helped to design the analysis. B.G.B. performed the analysis of the CoMMpass database. L.T.H. SL, A.K.N. and J.L.K. were the consulting and/or treating physicians of patients in this analysis. D.L.J. provided confirmatory FISH and karyotyping data from the pathology database. J.W., S.G. and Z.C. performed the statistical analysis of the data. C.C.H., M.V.D., V.A.G., L.H.B., S.L., A.K.N. and J.J.K. helped to design the analysis and interpret data.

Conflict of interest
L.T.H. declares research funding from Pharmacycics, Genentech, Kite Pharma, and ADC Therapeutics. C.C.H. declares research funding from Bristol-Myers Squibb and membership on an advisory committee for Celgene. Oncoproteptides, Adaptive Biotechnologies, and Janssen. M.V.D. declares membership in advisory boards for Amgen, Janssen, Roche, Celgene, Kite, and Lava Therapeutics. L.H.B. declares consultancy for Abbvie and Genentech, and honoraria and research funding from AstraZeneca. S.L. declares research funding from Amgen. A.K.N. declares consultancy and/or membership on an...
advisory committee for Spectrum Pharmaceuticals, Bristol-Myers Squibb, Adaptive Biotechnologies, Amgen, Celgene, Takeda, GlaxoSmithKline, and Janssen. JLK declares consultancy for Celgene, Takeda, Amgen Janssen, and Sanofi. The remaining authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at (https://doi.org/10.1038/s41408-019-0254-0).

Received: 3 May 2019 Revised: 16 September 2019 Accepted: 19 September 2019
Published online: 25 November 2019

References

1. Palumbo, A. et al. Revised International staging system for multiple myeloma: a report from International Myeloma Working Group. J. Clin. Oncol. 33, 2863–2869 (2015).
2. Hanamura, I. et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 108, 1724–1732 (2006).
3. Walker, B. A. et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 116, e56–e65 (2010).
4. Aver-Loiseau, H. et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J. Clin. Oncol. 30, 1949–1952 (2012).
5. Boyd, K. D. et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 26, 349–355 (2012).
6. Nencic, P. et al. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol. Blood Marrow Transplant 16, S48–S54 (2010).
7. Fonseca, R. et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 20, 2034–2040 (2006).
8. Aver-Loiseau, H. et al. Prognostic significance of copy-number alterations in multiple myeloma. J. Clin. Oncol. 27, 4585–4590 (2009).
9. Smets, J. et al. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib. Clin. Lymphoma Myeloma Leuk. 13, 123–130 (2013).
10. An, G. et al. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica. 99, 353–359 (2014).
11. Chang, H. et al. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains. Leuk. Res. 35, 95–98 (2011).
12. Shah, G. L. et al. Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leuk Lymphoma. 58, 1743–1751 (2017).
13. Dimopoulos, M. A. et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 24, 1719–1728 (2010).
14. Sawyer, J. R., Tricot, G., Mattow, S., Jagannath, S. & Barlogie, B. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood. 91, 1732–1741 (1998).
15. Chang, H. et al. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant. 45, 117–121 (2010).
16. Hebraud, B. et al. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia. 28, 675–679 (2014).
17. Barwick, B. G., Gupta, V. A., Vertino, P. M. & Bose, L. H. Cell of origin and genetic alterations in the pathogenesis of multiple myeloma. Front Immunol. 10, 1121 (2019).
18. Shaughnessy, J. D. et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 109, 2276–2284 (2007).
19. Shaughnessy, J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematol. Oncol. 10(Suppl 1), 117–126 (2005).
20. Teoh, P. J. et al. Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. Blood. 132, 1304–1317 (2018).
21. Samo, A. A. et al. MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy. Genes Chromosomes Cancer 57, 420–429 (2018).
22. Attal, M. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N. Engl. J. Med. 276, 4585–4590 (2007).
23. Durie, B. G. M. et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. The Lancet. 389, 519–527 (2017).
24. Barwick, B. G. et al. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nat. Commun. 10, 1911 (2019).
25. Stewart, A. K. et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood. 121, 1517–1523 (2013).
26. Walker, B. A. et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 33, 152–158 (2019).
27. Nooka, A. K. et al. Consolidation and maintenance therapy with lenalidomide, bortezomib, and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 28, 690–693 (2014).
28. Perrot, A. et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 132, 2456–2464 (2018).